

January 16, 2015



## Xenetic Biosciences to Hold Business Update Conference Call January 20th

LEXINGTON, Mass.-- **Xenetic Biosciences, Inc. (OTCBB: XBIO)**, a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, will hold a conference call on Tuesday, January 20, at 12:00 UK time, 7:00 a.m. ET. M. Scott Maguire, chief executive officer, and Colin Hill, chief financial officer and board member, will provide a business update and answer questions.

To access the conference call, U.K.-based participants should call 0800 368 0649, and participants in all other locations should call +44 20 3059 8125. The participant password will be: Sciences. A telephone replay will be available for seven days following the call's conclusion. Replay dial-in numbers are as follows: United Kingdom 0121 260 4861; United States 866-268-1947; and all other locations + 44 121 260 4861. Please provide conference ID 3245500# when accessing the replay. In addition, the call will be webcast and available at the Investor Relations section of [www.xeneticbio.com](http://www.xeneticbio.com) in the "Events and Presentations" tab.

### About Xenetic Biosciences

Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for creating next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs and OncoHist® for the development of novel oncology drugs focused on orphan indications. Xenetic's lead product candidates include ErepoXen®, an improved, polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease and OncoHist®, a recombinant human histone H1.3 molecule which Xenetic is developing for the treatment of refractory Acute Myeloid Leukemia (AML). Xenetic is developing a novel series of polysialylated blood coagulation factors through its license agreement with major shareholder Baxter International Inc. potentially worth as much as \$100 million plus royalty payments. Xenetic is also developing a broad pipeline of clinical candidates for next generation biologics and novel oncology therapeutics in a number of orphan disease indications. For more information, please visit the company's website at [www.xeneticbio.com](http://www.xeneticbio.com).

xbio-g

Xenetic Biosciences Inc.  
M. Scott Maguire, Chief Executive Officer  
781-778-7720  
[j.mccusker@xeneticbio.com](mailto:j.mccusker@xeneticbio.com)

or

**U.S. Contact:**  
LHA

Kim Sutton Golodetz, 212-838-3777

[kgolodetz@lhai.com](mailto:kgolodetz@lhai.com)

or

**UK/European Contact:**

Walbrook PR

Mike Wort, +44 (0)20 7933 8780

[mike.wort@walbrookpr.com](mailto:mike.wort@walbrookpr.com)

Source: Xenetic Biosciences, Inc.